sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_1926> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_1926> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB09039> ;
    a rdf:Statement ;
    rdfs:label "cerdelga is indicated for the long term treatment of adult patients with gaucher disease type 1 gd1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test see dosage and administration 2 1 cerdelga is a glucosylceramide synthase inhibitor indicated for the long term treatment of adult patients with gaucher disease type 1 who are cyp2d6 extensive metabolizers ems intermediate metabolizers ims or poor metabolizers pms as detected by an fda cleared test 1 limitations of use cyp2d6 ultra rapid metabolizers may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect 1 a specific dosage cannot be recommended for cyp2d6 indeterminate metabolizers 1 limitations of use patients who are cyp2d6 ultra rapid metabolizers urms may not achieve adequate concentrations of cerdelga to achieve a therapeutic effect see clinical studies 14 a specific dosage cannot be recommended for those patients whose cyp2d6 genotype cannot be determined indeterminate metabolizers see clinical studies 14" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB09039> bl:category bl:Drug .
}